Pre-clinical efficacy of trastuzumab deruxtecan plus sotorasib in <i>KRAS<sup>G12C</sup></i> -mutant non-small cell lung cancer and exploratory HER2 profiling in human tumors.

Although HER2 expression appeared numerically enriched in KRAS -mutant tumors compared with other oncogenic subsets, these findings did not reach statistical significance and require validation in larger cohorts.

also in 111,027 other papers

The sotorasib-T-DXd combination showed a trend toward greater regressions in tumors with higher HER2 expression post-sotorasib, though these analyses were not powered to detect a difference due to limited sample size ( Figure 2C ).

also in 53,322 other papers